3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3&bgr;
申请人:Syntex (U.S.A.) LLC
公开号:US06479490B2
公开(公告)日:2002-11-12
This invention relates to inhibitors of glycogen synthase kinase-3&bgr;, methods of treating diseases characterized by an excess of Th2 cytokines, and to 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives of Formula (I):
that are inhibitors of glycogen synthase kinase -3&bgr;, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
Here we report on the discovery of a series of maleimides which have high potency and good selectivity for GSK-3 beta. The incorporation of polar groups afforded compounds with good bioavailability. The most potent compound 34 has an IC(50) of 0.6 nM for GSK-3 beta, over 100-fold selectivity against a panel of other kinases, and shows efficacy in rat osteoporosis models. The X-ray structure of GSK-3 beta protein with 34 bound revealed the binding mode of the template and provided insights for future optimization opportunities. (C) 2010 Elsevier Ltd. All rights reserved.
3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
申请人:——
公开号:US20020052397A1
公开(公告)日:2002-05-02
This invention relates to inhibitors of glycogen synthase kinase-
3
&bgr;, methods of treating diseases characterized by an excess of Th
2
cytokines, and to
3
-indolyl-
4
-phenyl-
1
H-pyrrole-
2,5
-dione derivatives of Formula (I):
1
that are inhibitors of glycogen synthase kinase -
3
&bgr;, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.